Introduction {#Sec1}
============

Dilated cardiomyopathy (DCM), is a major and increasing cause of morbidity and mortality including sudden cardiac death, and affects approximately 40 out of 100,000 people, of which 30--50% have a genetic origin \[[@CR20]\]. Characterized by left ventricular dilation and systolic dysfunction, DCM often leads to terminal heart failure requiring cardiac transplantation \[[@CR13]\]. Most identified mutations affect genes encoding cytoskeletal proteins suggesting the impairment of force transmission \[[@CR28]\] or failing of the cardiomyocyte stretch sensor machinery \[[@CR22]\] as possible mechanisms underlying this disorder. However, also the mutations in sarcomeric proteins \[[@CR20]\] and nuclear membrane protein lamin A/C encoding genes \[[@CR17], [@CR32]\] may cause DCM. In addition, there is growing evidence that acquired factors such as autoimmunity, virus-induced chronic inflammation and impaired protein quality control may also contribute to the DCM development and heart failure \[[@CR21], [@CR38]\]. While the cause of the disease might be identified in many cases, the pathophysiological mechanisms that control the progression to the irreversible ventricular remodeling and heart failure are largely unknown \[[@CR14]\]. The analysis of sarcomeric cytoskeleton alterations, in particular of the M-band, might provide important clues to understand the pathological mechanisms in DCM.

The basic functional unit of the heart muscle is the sarcomere, which contracts due to sliding of myosin over actin filaments. The sarcomere cytoskeleton provides the scaffold for contractile filaments and includes three basic structural elements: the Z-disk and the M-band, two transverse structures anchoring the thin and thick filaments, and the elastic titin filaments connecting these longitudinally (Fig. [1](#Fig1){ref-type="fig"}a). The M-band is believed to organize the thick filament lattice and plays an important role in sarcomere mechanics \[[@CR3]\]. Its important structural elements are three closely related proteins of the myomesin family (Fig. [1](#Fig1){ref-type="fig"}b). Myomesin (or myomesin-1) \[[@CR16]\] appears to be an essential component of the sarcomere as it was found in all studied vertebrate muscles. Myomesin makes anti-parallel dimers which are believed to cross-link the myosin filaments in the M-band, a role analogous to α-actinin in the Z-disk \[[@CR23]\]. Myomesin interaction with the titin M-band portion \[[@CR30]\] might be crucial for the mechano-sensing and signaling functions mediated by the stretch-activated Ser/Thr-kinase domain of titin \[[@CR3], [@CR24], [@CR34]\]. Myomasp/LRRC39 was characterized recently as a novel M-band component associated with mechano-sensitive signaling pathways \[[@CR40]\]. Interestingly, the knockdown of myomasp leads to a significant down-regulation of myomesin-1 and myomesin-2 expression and decreases contractile force in heart muscle. The EH-myomesin splice isoform (see Fig. [1](#Fig1){ref-type="fig"}b), generated by inclusion of an elastic segment \[[@CR35]\] in the center of the molecule, is the main M-band component in the embryonic heart of higher vertebrates \[[@CR1]\] and is expressed in slow skeletal fibers of mice \[[@CR4]\]. Similarly, two other members of the myomesin protein family, M-protein and myomesin-3, show muscle-type specific expression patterns. M-protein is found in adult heart and fast skeletal muscle \[[@CR15]\], myomesin-3 appears in intermediate speed fibers of skeletal muscle but not in mouse heart at any developmental stage \[[@CR36]\]. This indicates that the M-band is a dynamic structure which adapts to the contractile parameters of a given muscle by varying the proportion of EH-myomesin and the level of M-protein and myomesin-3. Accordingly, this cytoskeletal system might represent a valid biomarker for pathological processes in the heart such as cardiomyopathy.Fig. 1Sarcomere cytoskeleton and M-band protein components. **a** Scheme of the sarcomere depicting the main components of the sarcomeric cytoskeleton (M-band, Z-disk and titin). **b** Myomesin (*white*), M-protein (*gray*) and myomesin-3 (*dark gray*) are composed of immunoglobulin-like domains (*ellipses*) and fibronectin type 3 domains (*rectangles*). The alternatively spliced EH-domain (EH) and the N-terminal domains are intrinsically unstructured

Aiming to establish the general relationships between the M-band alterations and heart function, we have designed a study comprising the analysis of mouse models and human myocardial biopsies. We first studied the M-band protein alterations in the hearts of two transgenic mouse models: the muscle LIM protein knockout mouse (MLP-KO), a well-established model for DCM \[[@CR5]\] and a mouse with stabilized β-catenin in the heart (β-catenin Δex3), which progressively develops a severe DCM phenotype resulting in heart failure and premature death \[[@CR19]\]. The disease progression was monitored by echocardiography and compared to the expression of myomesins. Human samples obtained from cardiac surgery patients were analyzed in the same way.

Methods {#Sec2}
=======

Animal breeding and maintenance {#Sec3}
-------------------------------

Transgenic knock-in mice expressing Cre recombinase under control of the myosin light chain 2v promoter \[[@CR9]\] were bred with β-catenin exon 3 floxed mice \[[@CR18]\] to generate animals with a stabilization of the protein restricted to the ventricular myocardium (MLC2v^Cre/wt^;β-catenin exon 3 ^flox/flox^) referred to later as β-catenin c∆ex3. Genotyping for Cre and β-catenin alleles was performed as described \[[@CR25]\]. MLP-deficient mice were described earlier \[[@CR5]\]. Age-matched WT controls were used for all experiments. Maintenance and animal experimentation are conforming to the Swiss Federal Veterinary Office guidelines.

Echocardiography {#Sec4}
----------------

Transthoracic echocardiography was performed by a blinded investigator using a 30-MHz probe and the Vevo 770 Ultrasound machine (VisualSonics). The rodent was placed under 1% isoflurane anesthesia via a nose cone and positioned on a 37°C heated surface. The eyes of the animals were protected from drying by lubricating ophthalmic gel. Under anesthesia, the following parameters were monitored: heart rate, body temperature (with rectal probe), ECG trace, and respiration. The hair was removed with an epilatory cream (deemed suitable for use in rodents).

The echocardiography images were obtained by placing warmed gel on the rodent, and the ultrasound probe actually never touched the animal itself due to the gel interface. The average anesthetic period lasted 10 min.

Echocardiographic analysis (all measured after the mouse was anesthetized) included basic left ventricular function parameters, cardiac output, stroke volume, left ventricular dimensions, and transvalvular flow indices. The study protocol was approved by the Swiss Federal Veterinary Office.

Antibodies {#Sec5}
----------

Monoclonal mouse anti-myomesin antibodies (clone B4) \[[@CR16]\], polyclonal rabbit anti-EH-myomesin (pR-anti-moEH for mouse) \[[@CR4]\] and anti-myomesin-3 antibodies (pR-anti-My3-N) \[[@CR36]\] were generated as described. The antibodies against human EH-myomesin (pR-anti-huEH) were generated in our laboratory (see details below). Monoclonal mouse anti-M-protein antibodies (clone AA259, IgA) were generously donated by Prof. D. O. Fürst (Potsdam, Germany). Monoclonal antibodies against sarcomeric α-actinin (clone EA-53) and polyclonal antibodies against all actin isoforms (A2066) were obtained from Sigma-Aldrich (Buchs, Switzerland). Monoclonal antibodies against β-catenin were obtained from Transduction Lab (cat.no. 610154) and antibodies against N-cadherin from Invitrogen (Zymed, 33-3900). Polyclonal antibodies against β-catenin were obtained from Sigma-Aldrich (C2206) and used for immunoblotting.

Horseradish peroxidase-conjugated anti-rabbit Igs (Calbiochem, San Diego, USA) and anti-mouse IgA (Sigma-Aldrich) were used as secondary antibodies for immunoblotting. Fluorescein isothiocyanate (FITC)-conjugated goat-anti-mouse IgA (Sigma-Aldrich), Cy3-conjugated goat-anti-mouse IgG (Fab-fragments) and Cy5-conjugated goat-anti-rabbit antibodies were used as secondary antibodies for immunofluorescence staining (Jackson Immuno Research, West Grove, PA, USA).

Generation of antibodies against human EH-myomesin {#Sec6}
--------------------------------------------------

Total RNA of human embryonic heart was isolated using the SV Total RNA isolation system (Promega, Wallisellen, Switzerland). The EH-fragment of human myomesin was amplified by RT-PCR on approximately 1 μg of total RNA with the Access RT-PCR system (Promega) using a standard RT-PCR protocol suggested by the manufacturer. Primers used for the amplification were derived from the human myomesin sequence (see "[RT-qPCR](#Sec10){ref-type="sec"}"). The segment was cloned into *Bam*HI and *Eco*RI sites of the bacterial expression plasmid pGEX-2T (Amersham Pharmacia Biotech, Otelfingen, Switzerland) and expressed in the *E. coli* strain BL-21 Star (Invitrogen, Basel, Switzerland). The soluble glutathione *S*-transferase fusion protein was purified from crude bacterial lysate by affinity chromatography on glutathione-agarose (Sigma). Antibodies against human EH-myomesin (anti-huEH) were generated by immunizing adult rabbits with this recombinant EH-fragment fused to glutathione *S*-transferase.

SDS-PAGE and immunoblotting {#Sec7}
---------------------------

The procedure was performed as described \[[@CR36]\]. Comparable tissue samples of the apex of the heart have been used for protein extraction. Quantification of the signal strength was done by a phosphor-imager (LAS-3000, Fujifilm).

Immunostainings {#Sec8}
---------------

The procedure was performed as described \[[@CR36]\]. Comparable sections from the lateral wall of the heart have been used for immunostainings.

Confocal microscopy {#Sec9}
-------------------

Analysis of the stained sections was carried out using a Leica (Leica Microsystems AG, Heerbrugg, Switzerland) confocal unit (Leica SP 5) equipped with an inverse microscope. DAPI was excited by a diode laser with 405-nm excitation, FITC fluorochrome was excited by an argon laser and Cy-3 and Cy-5 fluorochromes were excited by helium--neon lasers. Leica PL APO 63x/1.32 NA oil or PL APO 10x/0.3 NA oil immersion objectives were used. Image processing was done on a PC workstation using the image processing software Imaris (Bitplane AG, Zurich, Switzerland) and Photoshop (Adobe Systems, San Jose, USA).

RT-qPCR {#Sec10}
-------

Total RNA was isolated from comparable tissue samples of mouse or human tissues using TRIZOL Reagent (Invitrogen AG, Basel, Switzerland) or the RNeasy kit (Qiagen AG, Hombrechtikon, Switzerland). Reverse transcription was carried out on approximately 1 μg total RNA, cDNA was produced with the Thermoscript RT-PCR System (Invitrogen, Basel, Switzerland) and amplified using TAQ-polymerase (BioTherm DNA Polymerase; GeneCraft GmbH, Lüdinghausen, Germany). qPCR was performed using iTaq SYBR Green Supermix from Bio-Rad (Reinach, Switzerland) and a LightCycler^®^ 480 from Roche (Basel, Switzerland). Relative quantification of RNA levels was calculated by the ∆∆ct method \[[@CR33]\]. Primers used for the amplification of the fragments of mouse or human myomesin, M-protein and myomesin-3 were derived from the corresponding sequences \[myomesin: Ensembl gene Myom1, ENSMUSG00000024049 (mouse), ENSG00000101605 (human); M-protein: Ensembl gene Myom2, ID ENSMUSG00000031461 (mouse), ENSG00000036448 (human); myomesin-3: Ensembl gene Myom3, ENSMUSG00000037139 (mouse), ENSG00000142661 (human)\]. Sarcomeric alpha-actinin: Ensembl gene Actn2 ENSMUSG00000052374 (mouse) and ENSG00000077522 (human) and beta-actin: Ensembl gene Actb, ENSG00000075624 (human) have been used for normalization. For primer sequences, see Supplementary Table S1.

Human samples and patient demographics {#Sec11}
--------------------------------------

The study was approved by an institutional ethics committee and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Informed consent has been obtained from all patients included in this study. 40 tissue samples (ventricular and atrial) were obtained from 25 patients (16 male, 9 female) who underwent heart surgery. Patients were Caucasians, aged 30--62 years (plus a 0.5-year-old baby) and suffered from idiopathic (with unknown etiology) DCM (*N* = 13) or served as controls (*N* = 12). Control samples (non-dilated) were obtained from patients with hypertrophic cardiomyopathy (HCM) (*N* = 7) or from patients who either underwent adult cardiac surgery (*N* = 3) or congenital heart surgery (*N* = 2). Heart biopsies were obtained from two groups of DCM patients. The first group was classified as end-stage heart-failure (NYHA III--IV) and underwent only heart transplantation \[*N* = 10, EF = 12.7 ± 1.9%\], while the second group was supported by a left ventricular assist device (LVAD) for a certain period of time before heart transplantation (*N* = 3). All samples were processed in liquid nitrogen immediately after harvesting.

Patients in the control group received the standard medication such as aspirin, statins and beta-blockers. In addition, patients who have had valve replacement or repair received warfarin either lifelong or for a certain period of time. Patients who underwent congenital heart surgery mainly did not take any relevant medications. In contrast to this, HCM and DCM patients being in heart failure received standard heart failure medication including ACE inhibitors, beta-blockers, calcium channel inhibitors as well as diuretics.

Statistics {#Sec12}
----------

All data were considered as normally distributed and analyzed by unpaired, two-tailed Student's *t* test and for multiple comparisons, by one-way or two-way ANOVA. Differences were considered as statistically significant for *P* \< 0.05.

Results {#Sec13}
=======

Characterization of disease progression in transgenic mouse models for DCM by echocardiography {#Sec14}
----------------------------------------------------------------------------------------------

To evaluate the expression level of the myomesin genes in pathological situations in general, heart samples of mouse models for HCM or DCM were examined by RT-PCR analysis (Figure S1, supplementary material). These experiments showed that alterations in M-band composition are a hallmark of DCM compared to HCM models or controls.

Motivated by this finding, we analyzed the disease progression in detail, using two transgenic mouse models which progressively develop a severe DCM: the MLP-KO mouse \[[@CR5]\] and a mouse with stabilized β-catenin in the heart (β-catenin c∆ex3) \[[@CR19]\]. Several parameters describing the pump function and dimensions of the heart were measured at the age of 2 weeks, 5 weeks (Table [1](#Tab1){ref-type="table"}), 2 months and 4 months (Table [2](#Tab2){ref-type="table"}) in both mouse models and controls. The diastolic volume of the left ventricle (LV) was clearly enlarged in both models at the age of 4 months verifying the DCM phenotype (Fig. [2](#Fig2){ref-type="fig"}a). The hearts of MLP-KO and β-catenin c∆ex3 mice showed a significant reduction of the ejection fraction (EF) already at the age of 5 weeks which was even more pronounced at a higher age (Fig. [2](#Fig2){ref-type="fig"}b), demonstrating a continuous deterioration of cardiac function during disease progression. Both mouse models have chamber dilation with reduced wall motion, which was more pronounced in the β-catenin c∆ex3 mice at the age of 4 months (Fig. [2](#Fig2){ref-type="fig"}c).Table 1Echocardiography data (5 weeks)Wild type (*N* = 6)β-Catenin c∆ex3 (*N* = 6)MLP-KO (*N* = 6)Age (days)35 ± 035 ± 035 ± 0Female/male ratio4/23/33/3Body weight (g)15.5 ± 2.915.6 ± 2.814.3 ± 1.3Heart rate (beats/min)394 ± 46372 ± 42413 ± 29LVPW;d (mm)0.58 ± 0.030.72 ± 0.08\*0.72 ± 0.06\*LVPW;s (mm)0.78 ± 0.040.87 ± 0.10\*0.83 ± 0.05IVS;s (mm)0.78 ± 0.030.79 ± 0.080.83 ± 0.06LVID;d (mm)3.39 ± 0.373.75 ± 0.423.90 ± 0.11\*LVID;s (mm)2.31 ± 0.292.79 ± 0.49\*2.99 ± 0.10\*LV Vol;d (μl)47.6 ± 12.460.8 ± 15.165.8 ± 4.7\*LV Vol;s (μl)18.6 ± 5.630.5 ± 12.334.6 ± 2.9\*EF (%)61.2 ± 3.051.5 ± 9.2\*47.3 ± 3.0\*FS (%)31.9 ± 2.026.0 ± 5.5\*23.4 ± 1.8\*Ejection time (s)57.3 ± 4.654.6 ± 4.553.0 ± 3.1MV E/A1.79 ± 0.362.23 ± 1.101.69 ± 0.54Mean VcFc (circ/s)0.56 ± 0.050.48 ± 0.120.44 ± 0.06\*LV mass (mg)47.4 ± 8.769.7 ± 18.4\*74.9 ± 5.6\*LV mass/body weight (mg/g)3.06 ± 0.374.47 ± 1.18\*5.24 ± 0.39\*Cardiac function and ventricular dimensions of 5-week-old β-catenin c∆ex3 and MLP-KO mice assessed by transthoracic echocardiography*LVPW* left ventricular free wall, *IVS* interventricular septum, *LVID* left ventricular internal diameter, *FS* fractional shortening, *MV E/A* mitral valve E:A velocity ratio, *VcFc* circumferential fiber shortening, *d* diastole, *s* systole\* Significant differences compared to wild typeTable 2Echocardiography data (4 months)Wild type (*N* = 9)β-Catenin c∆ex3 (*N* = 9)MLP-KO (*N* = 6)Age (days)124 ± 5125 ± 5139 ± 4Female/male ratio4/56/34/2Body weight (g)28.1 ± 3.524.2 ± 2.9\*24.9 ± 2.0Heart rate (beats/min)397 ± 34421 ± 52360 ± 25LVPW;d (mm)0.73 ± 0.070.76 ± 0.090.71 ± 0.04LVPW;s (mm)0.98 ± 0.070.85 ± 0.10\*0.86 ± 0.11\*IVS;s (mm)0.89 ± 0.030.88 ± 0.070.79 ± 0.03\*LVID;d (mm)4.09 ± 0.115.07 ± 0.64\*4.64 ± 0.18\*LVID;s (mm)2.86 ± 0.114.33 ± 0.73\*3.69 ± 0.24\*LV Vol;d (μl)73.9 ± 4.5124.7 ± 34.9\*99.5 ± 9.2\*LV Vol;s (μl)31.0 ± 2.987.5 ± 32.2\*58.1 ± 8.8\*EF (%)58.02 ± 3.3231.65 ± 8.23\*41.66 ± 6.5\*FS (%)30.3 ± 2.315.1 ± 4.2\*20.5 ± 3.7\*Ejection time (s)54.9 ± 2.947.4 ± 4.5\*54.2 ± 2.9MV E/A1.94 ± 0.624.84 ± 3.37\*4.01 ± 1.43\*Mean VcFc (circ/s)0.55 ± 0.050.31 ± 0.06\*0.38 ± 0.08\*LV mass (mg)81.5 ± 8.0134.5 ± 40.1\*97.2 ± 9.3\*LV mass/body weight (mg/g)2.92 ± 0.295.62 ± 1.75\*3.91 ± 0.36\*Cardiac function and ventricular dimensions of 4-month-old β-catenin c∆ex3 and MLP-KO mice assessed by transthoracic echocardiography*LVPW* left ventricular free wall, *IVS* interventricular septum, *LVID* left ventricular internal diameter, *FS* fractional shortening, *MV E/A* mitral valve E:A velocity ratio, *VcFc* circumferential fiber shortening, *d* diastole, *s* systole\* Significant differences compared to wild typeFig. 2Echocardiography of DCM models. **a** Left ventricular diastolic volume measurements confirming the DCM phenotype in MLP-KO (*black*) and more severe in β-catenin c∆ex3 animals (*gray*) compared to controls (*white*). **b** Ejection fraction of control (*white*), β-catenin c∆ex3 (*gray*) and MLP-KO (*black*) mice demonstrating the continuous decrease in heart function during progression of the disease. *Error bars* represent standard deviation, *N* ≥ 6 for each subgroup. *Asterisks* mean significant differences compared to control groups. **c** M-mode echocardiographic tracings in control (*left*), β-catenin c∆ex3 mice (*center*) and MLP-KO (*right*) at the age of 4 months. Left ventricular dimensions are indicated by *white lines*

Alterations in expression of myomesin proteins during the development of DCM {#Sec15}
----------------------------------------------------------------------------

To investigate whether alterations in the protein composition of the sarcomeric M-band can be used as biomarker for processes occurring in diseased heart, we analyzed the accumulation of myomesin proteins in DCM mouse models. Protein levels in the left ventricle of MLP-KO and β-catenin c∆ex3 were measured by Western blot at different time points and compared to controls. These experiments showed a significant up-regulation of EH-myomesin already at the early stage of DCM in MLP-KO mice (2 weeks), whereas in the β-catenin c∆ex3 mice the up-regulation does not start before 5 weeks of age (Fig. [3](#Fig3){ref-type="fig"}b). At the age of 4 months, EH-myomesin level is significantly higher in both DCM models by a factor of about two. There is a relatively high variability in the accumulation of EH-myomesin between individual animals (Fig. [3](#Fig3){ref-type="fig"}a, EH). At the age of 2 months, M-protein is down-regulated in both DCM models, but more prominent in the MLP KO mouse (Fig. [3](#Fig3){ref-type="fig"}a, M-pr). Interestingly, an up-regulation of myomesin-3 can be detected only in the MLP-KO mice (Fig. [3](#Fig3){ref-type="fig"}a, Myo3), which is consistent with the RT-PCR analysis (Figure S1). In addition, β-catenin is clearly accumulated in both mouse models (Fig. [3](#Fig3){ref-type="fig"}a, β-cat), in accordance with previous studies, reporting the up-regulation of adherens junction protein components in dilated heart \[[@CR31]\]. To confirm that the up-regulation of EH-myomesin in the heart is a general phenomenon of mouse DCM models, two additional models have been analyzed by Western blot (Supplementary Table S2). In addition, a non-genetic mouse model for heart failure (ischemic cardiomyopathy due to chronic left anterior descending artery ligation \[[@CR27]\]) was analyzed and showed up-regulation of EH-myomesin in the scar region of the myocardial infarct, where the ventricular wall is very thin (Supplementary Figure S2).Fig. 3Expression of myomesin proteins during development of dilated cardiomyopathy. **a** Immunoblot analysis of mouse heart protein extracts of control, β-catenin c∆ex3 mice and MLP-KO mice (age 2 months). EH-myomesin (EH) is accumulated in several animals suffering from DCM with variability between individual mice. A slight down-regulation of M-protein is detectable in the β-catenin c∆ex3 mice, which is more pronounced in the MLP-KO mice at the age of 2 months (M-pr). Myomesin-3 up-regulation is detectable only in the MLP-KO mice (Myo3). β-Catenin (β-cat) is accumulated in both mouse models, with the β-catenin c∆ex3 mice showing expression of the truncated form (*lower bands*) in addition to the normal protein (*upper bands*). **b** Quantification of EH-myomesin levels during disease development shows an accumulation already at 2 weeks in the MLP-KO mice (*black columns*). In the β-catenin c∆ex3 model (*gray columns*) a significant up-regulation of this isoform is detectable at the age of 8 weeks. At 4 months, both DCM models show an accumulation of EH-myomesin. Expression levels are normalized on sarcomeric actin levels and compared to control mice. *Error bars* represent standard deviation, *N* ≥ 6 for each subgroup. *Asterisks* mean significant differences compared to control groups. *P* values compared to control were as follows: 2 weeks (β-catenin c∆ex3, *P* = 0.163; MLP KO, *P* = 0.007), 5 weeks (β-catenin c∆ex3, *P* = 0.089; MLP KO, *P* = 0.001), 2 months (β-catenin c∆ex3, *P* = 0.016; MLP KO, *P* = 0.067), 4 months (β-catenin c∆ex3, *P* = 0.016; MLP KO, *P* = 0.041). *w* weeks, *m* months

Accumulation of EH-myomesin correlates with dilation and impairment of heart function {#Sec16}
-------------------------------------------------------------------------------------

To analyze the potential of EH-myomesin up-regulation as a marker for DCM and to investigate its role in disease development, protein levels of this isoform were compared to cardiac parameters measured by echocardiography. Already at the age of 5 weeks, there was a strong correlation between the left ventricular (LV) systolic volume and EH-myomesin accumulation (correlation coefficient *R* = 0.82, Fig. [4](#Fig4){ref-type="fig"}a). At this age, all MLP-KO mice suffer from a significant dilation including EH-myomesin up-regulation, whereas the β-catenin c∆ex3 animals show a relatively wide variation in LV systolic volume. Furthermore, the ejection fraction was measured and compared with the accumulation of EH-myomesin (Fig. [4](#Fig4){ref-type="fig"}b). At the age of 5 weeks, two out of six β-catenin c∆ex3 animals still had a normal heart function with an ejection fraction around 60% and normal levels of the EH-myomesin isoform. However, four out of six of the β-catenin c∆ex3 animals had a significantly reduced ejection fraction compared to controls and showed up-regulation of this protein. The coefficient *R* = −0.86 highlighted the strong negative correlation between ejection fraction and EH-myomesin accumulation. The correlation coefficients between EH-myomesin and the cardiac parameters LV systolic volume, LV systolic internal diameter and ejection fraction were compared at different stages of the disease (Fig. [4](#Fig4){ref-type="fig"}c). The strongest correlations were found at the age of 5 weeks and were slightly reduced at later stages of the disease.Fig. 4Comparison of EH-myomesin expression with heart parameters. **a** Left ventricular (LV) volume in systole measured by echocardiography at the age of 5 weeks correlates with EH-myomesin expression in MLP-KO (*oblique squares*, *N* = 6) and β-catenin c∆ex3 mice (*triangles*, *N* = 6). The β-catenin c∆ex3 transgenic animals show a relatively wide distribution in volume, whereas the MLP-KO mice have a significant dilation including up-regulation of EH-myomesin expression already at this age. The strong correlation between LV volume and EH-myomesin accumulation is reflected by a correlation coefficient of *R* = 0.82. Control mice are shown as *squares* (*N* = 6). **b** At the age of 5 weeks, the controls (*squares*) and some of the β-catenin c∆ex3 animals (*triangles*) have a normal ejection fraction (about 60%) including normal levels of EH-myomesin. Animals with a clearly reduced ejection fraction have accumulated this protein significantly. The strong negative correlation is reflected by a correlation coefficient *R* = −0.86. **c** Table showing the correlation coefficients for the relations between EH-myomesin protein levels and LV systolic volume (LV Volume, s), LV systolic internal diameter (LVID, s) or % ejection fraction (EF%). The strongest correlations were found at the age of 5 weeks. *5w* 5 weeks, *2m* 2 months, *4m* 4 months

EH-myomesin is up-regulated in cardiomyocytes of mouse DCM models in a cell-specific fashion {#Sec17}
--------------------------------------------------------------------------------------------

The expression of EH-myomesin and M-protein was analyzed at the cellular level by immunofluorescence analysis of mouse heart cryosections (age 4 months, Fig. [5](#Fig5){ref-type="fig"}). In dilated hearts, these proteins changed their expression in a cell-specific manner: EH-myomesin is accumulated in both DCM models with certain heterogeneity, whereas M-protein is slightly down-regulated.Fig. 5Heterogeneous accumulation of EH-myomesin in cardiomyocytes of mouse DCM models. Cryosections of mouse heart ventricles of control (**a**, **d**, **g**, **k**, **n**), β-catenin c∆ex3 (**b**, **e**, **h**, **l**, **o**) and MLP KO (**c**, **f**, **i**, **m**, **p**) mice at the age of 4 months quadruple-stained with antibodies against M-protein (**d**--**f**; *green* in overlays), EH-myomesin (**g**--**i**; *blue* in overlays), DAPI (**k**--**m**; *red* in overlays) and N-cadherin (**n**--**p**). A down-regulation of M-protein is apparent in single cardiomyocytes of the β-catenin c∆ex3 transgenic animals. In contrast, M-protein is relatively homogenously expressed in MLP KO (**f**) and control mice (**d**). EH-myomesin is accumulated in both DCM models (**h**, **i**; *blue* in **b**, **c**) with certain heterogeneity. In the β-catenin c∆ex3 transgenic animals, the same cardiomyocytes, which show an up-regulation of EH-myomesin (**h**), have reduced levels of M-protein (**e**), leading to a more embryonic-like phenotype. A big accumulation of nuclei can be detected in the hearts of β-catenin c∆ex3 mice (**l**, *red* in overlay), including fibrosis (regions without M-band staining) and some hypertrophied nuclei. The accumulation of the intercalated disk component N-cadherin (**n**--**p**) is visible in both DCM mouse models. *Scale bar* 100 μm

The β-catenin c∆ex3 mouse progressively develops severe DCM and dies at the latest of 6 months. To evaluate the expression of M-band components at the end-stage of DCM in more detail, β-catenin c∆ex3 mice were analyzed at the age of 5 months and compared to MLP-KO and control mice (Fig. [6](#Fig6){ref-type="fig"}). In these hearts, EH-myomesin expression showed considerable heterogeneity with a complete switch to an embryonic phenotype in some cardiomyocytes (Fig. [6](#Fig6){ref-type="fig"}, asterisk in b, e, h). M-protein was significantly down-regulated in both DCM models compared to controls (Fig. [6](#Fig6){ref-type="fig"}d--f). This down-regulation is rather homogenous in the MLP-KO, whereas in the β-catenin c∆ex3 animals it was patchy in respect to single cardiomyocytes. β-Catenin (Fig. [6](#Fig6){ref-type="fig"}k--m, red in a--c) was up-regulated in both DCM models, as described \[[@CR12]\].Fig. 6Expression of M-band components at the end-stage of DCM. Cryosections of mouse heart ventricles of control (**a**, **d**, **g**, **k**), β-catenin c∆ex3 (**b**, **e**, **h**, **l**) and MLP-KO (**c**, **f**, **i**, **m**) mice at the age of 5 months triple-stained with antibodies against M-protein (**d**--**f**; *green* in overlays), EH-myomesin (**g**--**i**; *blue* in overlays), and β-catenin (**k**--**m**; *red* in overlays). M-protein is homogenously expressed in control mice (**d**), whereas in β-catenin c∆ex3 (**e**) and MLP-KO (**f**) transgenic animals it is significantly down-regulated. This down-regulation is homogenous in the MLP-KO, whereas in the β-catenin c∆ex3 animals it is extremely heterogeneous. EH-myomesin is up-regulated extremely heterogeneously in the β-catenin c∆ex3 transgenic animals. Some single cardiomyocytes show a switch to an embryonic phenotype of M-bands, with higher level of EH-myomesin expression and very low M-protein expression level (*asterisk* in **e**, **h**). β-Catenin is strongly accumulated in both DCM models (**l**, **m**; *red* in **b**, **c**). *Scale bar* 20 μm

Up-regulation of EH-myomesin in human DCM patients {#Sec18}
--------------------------------------------------

To check the expression of the myomesin isoforms in the heart of humans suffering from cardiomyopathy, RT-qPCR analysis was carried out using total RNA isolated from heart biopsies of patients suffering from DCM and compared to non-dilated control hearts. Myomesin was expressed evenly (Figure S3), whereas the EH-myomesin isoform was significantly up-regulated in the hearts of most patients suffering from DCM compared to non-dilated controls and to patients suffering from HCM, with considerable variability in the expression levels (Fig. [7](#Fig7){ref-type="fig"}, Fig. S4). No significant accumulation of EH-myomesin could be detected in hearts of patients treated by a LVAD. In DCM patients without LVAD, the up-regulation of EH-myomesin was 41 times compared to controls. The correlation coefficient between % ejection fraction and the expression level of EH-myomesin was *R* = −0.64, confirming the correlation in the transgenic DCM mouse models. In all patients with an ejection fraction below 20%, EH-myomesin levels were up-regulated at least 10 times compared to control patients. We have found no indication that medication affected the expression of EH-myomesin.Fig. 7EH-myomesin is re-expressed in human patients suffering from DCM. RT-qPCR analysis of human patients suffering from DCM or HCM using primers specific for EH-myomesin. This isoform is massively up-regulated (41 times) in the hearts of patients suffering from DCM (*right column*, *N* = 10) compared to non-dilated control hearts (*N* = 5) and hearts of patients suffering from HCM (*N* = 7). DCM patients under treatment with a left ventricular assist device (LVAD, *N* = 3) show no significant re-expression of the EH-myomesin isoform. Sarcomeric α-actinin was used for normalization. *HCM* hypertrophic cardiomyopathy, *DCM* dilated cardiomyopathy, *LVAD* left ventricular assist device. *Error bars* represent standard deviation. *Asterisk* means significant difference compared to the other tested groups

Furthermore, stainings of cryosections of human hearts were performed to confirm the re-expression of EH-myomesin in human DCM patients (Fig. [8](#Fig8){ref-type="fig"}, right) compared to a healthy control (Fig. [8](#Fig8){ref-type="fig"}, left). The sections were triple stained with antibodies against M-protein, EH-myomesin, and β-catenin. M-protein was homogenously expressed in both hearts, whereas EH-myomesin was re-expressed in single cardiomyocytes of the DCM patients. These results were consistent with the data obtained from mouse DCM models.Fig. 8EH-myomesin is up-regulated in the heart of human DCM patients in cell-specific fashion. Confocal images of cryosections of human hearts of control (**a**, **c**, **e**, **g**) and a DCM patient (left ventricle; **b**, **d**, **f**, **h**) triple-stained with antibodies against M-protein (**c**, **d**; *green* in overlays), EH-myomesin (**e**, **f**; *blue* in overlays), and with β-catenin (**g**, **h**; *red* in overlay). M-protein is homogenously expressed in both hearts (**c**, **d**), whereas EH-myomesin is up-regulated in the DCM patient in a cell-specific manner. *Scale bar* 10 μm

Myomesin-3 is expressed in human skeletal muscle and adult heart {#Sec19}
----------------------------------------------------------------

To analyze whether the myomesin genes were expressed in a tissue-specific manner also in human, RT-PCR analysis was performed on total RNA isolated from different human tissues (Figure S5). The muscle tissue samples were tested with primers specific for different myomesins (Table S1). Myomesin was detectable in all types of human-striated muscle, whereas EH-myomesin was found in the embryonic heart. M-protein was highly expressed in embryonic skeletal muscle and adult heart of human. In contrast to mouse, myomesin-3 was detectable not only in skeletal muscle, but also in the adult human myocardium.

Discussion {#Sec20}
==========

Previous studies described the M-band as a dynamic element of the sarcomeric cytoskeleton which adapts to the contractile regime of a particular muscle by varying the type and number of different myomesin molecules cross-linking the thick filaments \[[@CR3]\]. Here, we characterize the M-band protein composition in mouse and human heart, in both healthy and pathological situations. We show that expression patterns of myomesins correlate with the physiological parameters of the heart muscle, and vary depending on species, developmental stage or type of cardiomyopathy (Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}).Table 3Summary of expression data of myomesin proteins in the heart of mouse and humanMouse heartHuman heartEmbryonicAdultEmbryonicAdultEH-myomesin+Low level+Low levelM-protein−+−+Myomesin-3−----+While in embryonic development EH-myomesin is the main M-band component in the heart of both mouse and human, the adult hearts show species-specific expression patterns of myomesins. The human myocardium is characterized by higher levels of myomesin-3Table 4Summary of alterations in expression of myomesins in DCM in mouse and humanc∆ex3 β-cat miceMLP-KO miceHuman DCMEH-myomesin↑↑↑M-protein↓↓--Myomesin-3--↑--The up-regulation of EH-myomesin is the main marker for DCM in both mouse and human heart. Changes between M-protein and myomesin-3 expression might discriminate between different DCM mouse models↑ up-regulation, ↓ slight down-regulation, --: no alteration detectable

The M-band protein composition is identical in embryonic heart of mouse and human and is restricted to the EH-myomesin isoform. However, this isoform is down-regulated around birth and the adult hearts show distinct expression patterns of myomesins (Table [3](#Tab3){ref-type="table"}). Human myocardium accumulates much more myomesin-3 compared to mouse heart. Thus, the M-band composition of mouse heart resembles fast skeletal fibers, while that in human heart is more close to intermediate speed fibers \[[@CR36]\]. This can be explained by different physiological demands to the M-bands. The mouse heart beats much faster than the human one, and the mouse heart myosin produces much higher contraction speed \[[@CR7]\]. Both parameters probably necessitate the presence of a "faster" M-band in mouse myocardium. Our observations showed the limitations in direct applicability of results obtained from mouse models for the human heart. The differences in physiological characteristics and in the cytoskeletal design between mouse and human hearts should always be taken into account by any prediction.

Our experiments showed an accumulation of EH-myomesin in both mouse models of DCM (MLP-KO and β-catenin c∆ex3), which correlated well with the decrease of ejection fraction at the early stage of disease. This suggests EH-myomesin as an early marker of DCM. In addition to EH-myomesin up-regulation, we found that some DCM mouse models (e.g. MLP-KO mice) up-regulated myomesin-3 expression, which might represent a fine-tuning of the M-band to specific biomechanical alterations. As discussed above, the adult human heart has a different M-band composition compared to mouse. However, the up-regulation of EH-myomesin was a constant characteristic also of DCM in human heart, irrespective of the cause of the disease. We found that expression of EH-myomesin is dramatically up-regulated (41-fold, *P* \< 0.001) in the DCM group compared to the control and HCM groups. The up-regulation of EH-myomesin was much lower in DCM hearts supported by a LVAD.

The up-regulation of EH-myomesin in DCM is consistent with the reported re-expression of fetal isoforms of sarcomeric proteins in the dilated heart \[[@CR10]\]. Accordingly, the appearance of the myomesin isoform containing the additional elastic EH-fragment matches the up-regulation of compliant titin isoforms in human DCM \[[@CR26], [@CR29]\], suggestive of a correlative adaptation of both cytoskeletal structures in this pathological situation.

What might be the reason for such a remodeling of the sarcomere cytoskeleton? We propose that it is a general adaptation to the altered contractile mechanics of the sarcomere in the dilated heart. Indeed, our observations show that up-regulation of EH-myomesin is universal for all tested DCM hearts, irrespectively of species and regardless to the cause of the disease. Also, the increase of the EH-myomesin expression correlates well with the decrease of the heart pumping function and correspondingly to the increase of volume overload in the dilated heart. Previously, EH-myomesin expression was reported in fibers working in the eccentric contraction regime in mouse skeletal \[[@CR4]\] and rat extraocular muscles \[[@CR39]\]. The sarcomere in the dilated heart has to contract in overstretched conditions as well, requiring the switch to a "fuzzy sarcomere" design, which is more stable in eccentric conditions \[[@CR2]\]. The application of LVAD leads to a decreased load of the contracting sarcomere, which correlates with much lower levels of EH-myomesin in the LVAD supported hearts.

The remodeling to a more embryonic type of cytoskeleton might also be an adaptive response to calcium signaling defects in the failing heart. Indeed, the failing human heart shows slower relaxation kinetics caused by delayed Ca^2+^ re-uptake \[[@CR8]\] due to reduced SERCA function, enhanced NCX function, and greater Ca^2+^ leak from the sarcoplasmic reticulum \[[@CR6]\]. In the embryonic heart, the Ca^2+^ re-uptake is compromised by immature excitation--contraction coupling \[[@CR11]\]. The LVAD support improves the contractility of the failing heart and shortens the rate of the Ca^2+^ decay to the level of non-failing heart \[[@CR8]\]. This correlates with our finding that EH-myomesin expression in LVAD supported hearts does not differ significantly from the non-dilated control hearts.

We have found that the M-band composition changes in a cell-autonomous fashion in the failing heart. In the heart of β-catenin c∆ex3 mice, some cardiomyocytes switch completely to the embryonic M-band phenotype by up-regulating EH-myomesin and down-regulating M-protein, whereas others keep the phenotype of adult cardiomyocytes with high levels of M-protein and very low levels of EH-myomesin. The down-regulation of M-protein is not detectable in the human DCM hearts, but EH-myomesin is also up-regulated in a cell-specific manner. We intend that increased myocardial strain in dilated heart might provoke the up-regulation of EH-myomesin and "patchy", cell-specific expression pattern might be caused by a different mechanical burden on certain myocytes. This suggestion is supported by the observation that a strong up-regulation of EH-myomesin is observed in the scar region of the heart remodeled after myocardial infarction, as the ventricular wall is very thin in the scar region and the slim layer of remaining myocytes is subjected to huge contractile stress. This is a very important observation, because all molecular alterations found by previous studies in the diseased myocardium were averaged values for the whole heart and did not consider the divergence between individual cardiomyocytes. We, therefore, hypothesize that M-band alterations might be part of a general adaptation of the sarcomeric cytoskeleton to unfavorable working conditions in the failing heart, and might also affect the mechanical properties of the cardiomyocytes. The progressive cell-to-cell heterogeneity through the myocardial wall would impair the force transmission and might have important implications for the mechanism of cardiac failure. Computer models showed that occurrence of mechanical non-uniformities in myocardial muscle might lead to spontaneous Ca^2+^ release from sarcoplasmic reticulum and initiate arrhythmogenic waves \[[@CR37]\]. Thus, the cytoskeletal alterations by DCM, initially driven by a compensatory mechanism, may eventually become maladaptive with disease progression. However, further studies are needed to clarify the role of cytoskeletal non-uniformities in the development of arrhythmias in the failing heart.

Here, we present for the first time that EH-myomesin, the dominant myomesin isoform in the embryonic heart, is up-regulated in DCM. Since we have previously shown that this myomesin isoform is associated with a higher degree of M-band elasticity \[[@CR35]\], this finding might give new insights into the understanding of progressive ventricular dilation on a structural level. Furthermore, the up-regulation of EH-myomesin at early stages of the disease and its correlation to the impairment of ventricular function may be used for a better characterization of DCM in human patients.
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